JP3225777U - Oral tablets - Google Patents

Abstract

The present invention provides an oral tablet containing a complex composition, which is easy to carry and ingest, and is useful for preventing liver damage. The oral tablet according to the present invention includes a solid tablet body (10) formed by mixing a powdery composite compound, wherein the tablet body (10) has a circular annular surface and an opposite annular surface. Both end faces include two end faces connected to both ends, each of the two end faces has a curved convex shape, and the composite formulation contains a turmeric extract, a iwakakei extract, and other edible additives. [Selection diagram] Fig. 1

Description

  The present invention relates to an oral tablet, and more particularly to an oral tablet useful for preventing liver damage.

  The liver is a necessary organ for the metabolism and detoxification of the human body. When liver function is impaired, it can cause metabolic disorders, affect the functions of other organs, and endanger life significantly.

  Studies show that fatty liver is one of the most common forms of liver dysfunction, and the six main causes of fatty liver are obesity, hypertriglyceridemia, and abnormal blood glucose metabolism (diabetes Etc.), excessive drinking, hepatitis C, drugs. Although fatty liver does not cause immediate harm to life, health concerns are strongly suggested.

  Because fatty liver is a reversible disease, the best way to improve it is to exercise properly and eat a healthy diet, but studies have shown that taking certain nutrients It has been found to help reduce liver disease and damage. At present, the biggest challenge is how to produce a food that is easy to carry, ingest, and useful for preventing liver damage.

  The present invention has been made in view of the above, and a main object of the present invention is to provide an oral tablet that contains a complex formulation, is easy to carry, easily ingests, and is useful for preventing liver damage.

The present invention relates to an oral tablet,
A tablet body comprising a solid form formed by mixing the compound preparation in powder form, wherein the tablet body comprises a circular annular surface and two end surfaces connected to opposite ends of the annular surface; Each of the two end surfaces has a curved convex shape, and is characterized in that the composite preparation contains a turmeric extract, a rock extract, and other edible additives.

  It is preferable that the tablet further includes a film coating layer covering the outer surface of the tablet body.

  The oral tablet of the present invention is made into a solid form of a tablet body by mixing and mixing turmeric extract, iwabenkei extract and the like, which is useful for preventing liver damage and easy to carry. In addition, the synergistic effect of the turmeric extract and Iwaenkei extract lowers the ALT and AST levels in plasma, improves the activation of antioxidant enzymes (GSH-Px) in the liver, This has the effect of suppressing the formation of fibers.

1 is an external perspective view of a preferred embodiment of the present invention. FIG. 2 is a side sectional view of a preferred embodiment of the present invention. FIG. 3 is a three-dimensional cross-sectional view of a preferred embodiment of the present invention.

  As shown in FIG. 1 to FIG. 3, the oral tablet of the present invention includes a tablet body 10, which is a solid form obtained by mixing a compound preparation in powder form, and has a diameter of 1 cm, It comprises a circular annular surface 3.5 mm in height and two end surfaces connected to opposite ends of the annular surface, each of which has a curved convex shape. The composite formulation includes Turmeric Extract, Rhodola Rosea Extract, and other edible additives, wherein the other edible additives are corn gluten meal, taurine (Taurin). ), Vitamin E (Vitamin E), wherein the turmeric extract is curcumin, which accounts for 11.17% to 16.77% by weight of the oral tablet of the present invention. The extract may be salidroside, which accounts for 0.12% to 0.18% by weight of the oral tablet of the present invention. In this example, the weight of the oral tablet was 501 milligram (mg) ± 5%, of which curcumin content was 70 mg ± 14 mg and salidroside content was 0.75 ± 0.15 mg.

  Research has shown that curcumin has anti-inflammatory and antioxidant properties, thus reducing the lipid peroxidation of the cell membrane of hepatocytes and protecting the liver from damage by restoring damaged hepatocytes to some extent. Salidroside has antioxidant, lipid peroxidation inhibitory, and anti-inflammatory effects.

  The oral tablet of the present invention preferably further includes a coating layer 20. The coating layer 20 is transparent and covers the outer surface of the tablet main body 10, and further includes polyvinylpyrrolidone, microcrystalline α-cellulose, and cross-linked sodium carboxymethyl cellulose (Cross-Linked Sodium Carboxyme). Cellulose), silicon dioxide (Silicon Dioxide), magnesium stearate (Magnesium Stearate), hydroxypropyl methylcellulose (hydroxypropylmethylcellulose, HPMC), polyethylene glycol (Polyethylene glycol, mainly oral, PEG) It is used to make the agent hard to deteriorate, easy to store and easy to take.

  Whether the oral tablet of the present invention is useful for protection and improvement of liver function was reported by the Ministry of Health and Welfare of the Taiwan Government, in which the method of evaluating the liver protection effect of health foods induced carbon tetrachloride-induced chemical liver injury. Animal experiments were performed and evaluated in accordance with the norm.

In that experiment, 50 6-week-old male Wistar rats were arbitrarily divided into 10 groups to make 5 groups, one of which was a control group and 4 were carbon tetrachloride (CCl ₄ ). Olive oil (0.2 ml / 100 g body weight) was orally administered twice a week to rats in the experimental group and rats in the control group were administered orally to rats in the CCl ₄ experimental group in order to induce chronic hepatitis. _{% CCl 4 (0.2ml / 100g body} weight) twice a week, total of 8 weeks, administered orally, further each into four sets of CCl ₄ experimental groups, during the experiment period (liver damage by CCl ₄ 1 week before induction) 0.5% carboxymethylcellulose (Carboxymethyl Cellulose, CMC) once daily, oral tablet 1x dose, oral tablet 2x dose, It gave three times the dose of the tablet.

Subsequently, from all experimental rats, one week before the start of the experiment to induce liver injury using CCl _4, and at the 0th week, the 1st week, the 3rd week, and the 6th week of the start of the experiment to induce liver injury. Blood is collected, fasted 8 to 12 hours before blood collection, and 4 hours after administration of the test substance or CMC, blood is collected from the tail to examine the biochemical function of the liver. At the end of the 8th week, the rats are anesthetized and bled from the abdominal aorta at the same time as they are killed, and the liver and spleen are harvested and examined for further laparotomy.

  The recommended dose of the oral tablet of the present invention was 4 tablets per day and 501 mg per tablet. The oral dose of the rat was calculated based on a human-to-rat metabolic conversion ratio of 6.2, and calculated to be 2004 mg / 60 kg (human weight) x 6.2 = 207 mg / kg per rat per day. . 207 mg / kg is a single dose for humans.

The following are statistical data obtained by comparing rats that received different doses of the oral tablet of the present invention with rats with CCl ₄ hepatic injury that received only the CMC solution through animal experiments.

1. The CCl ₄ × CMC group had an AST value in plasma of 2342.9 ± 1066.5 (U / L) at the 8th week of the experiment, and the CCl ₄ × oral tablet single dose group had 739. 9 ± 399.2 (U / L). The AST activity of the CCl ₄ × oral tablet set was found to be significantly lower than that of the CCl ₄ × CMC set.

2. The CCl ₄ × CMC group had a plasma ALT value of 1932.7 ± 896.7 (U / L) at the 8th week of the experiment, and the CCl ₄ × oral tablet single dose group had 912. 1 ± 553.6 (U / L). The ALT activity of the CCl ₄ × oral tablet set was found to be significantly lower than that of the CCl ₄ × CMC set.

3. In the CCl ₄ × CMC group, the plasma Albumin concentration at the 8th week of the experiment was 2.52 ± 0.39 (g / dL), and the CCl ₄ × oral tablet 1-fold dose group was 2. 97 ± 0.62 (g / dL). The Albumin concentration of the CCl ₄ × oral tablet group was found to be significantly higher than that of the CCl ₄ × CMC group.

4, CCl ₄ × CMC sets the absolute spleen weight after the experiment is 2.19 ± 0.19 (g), the relative weight a 0.49 ± 0.12 (%), CCl 4 × oral tablet In the 1-dose group, the absolute weight of the spleen after the experiment is 1.51 ± 0.57 (g), and the relative weight is 0.35 ± 0.15 (%). The absolute weight and relative weight of the spleen of the CCl ₄ × oral tablet set were found to be significantly lower than that of the CCl ₄ × CMC set.

5, CCl ₄ × CMC sets the concentration of antioxidant (glutathione) in liver after experiments a 1.4 ± 0.3 (μmol / g) , CCl 4 × oral tablet 1 times the dose set is 1.8 ± 0.5 (μmol / g). In addition, it was found that the concentration of antioxidant (glutathione) in the liver of the CCl ₄ × oral tablet group tended to increase.

6. The CCl ₄ × CMC group had a liver protein concentration of 68.4 ± 10.7 (mg / g tissue) after the experiment, and the CCl ₄ × oral tablet 1-fold dose group had 80.4 ± 7. 8 (mg / g tissue). In addition, it was found that the liver protein concentration of the CCl ₄ × oral tablet group was significantly higher than that of the CCl ₄ × CMC group.

7. The CCl ₄ × CMC group had a liver hydroxyproline concentration of 604.6 ± 63.6 (μg / g tissue) after the experiment, and the CCl ₄ × oral tablet single dose group had 377.8 ± 74. 9 (μg / g tissue). In addition, the liver hydroxyproline concentration of the CCl ₄ × oral tablet group was found to be significantly lower than that of the CCl ₄ × CMC group.

8. The CCl ₄ × CMC group had a hepatic GSH-Px activity of 822.9 ± 237.0 (mU / mg protein) after the experiment, and the CCl ₄ × oral tablet 1-fold dose group showed 119.4 ± 248.5 (mU / mg protein). In addition, the liver GSH-Px activity of the CCl ₄ × oral tablet group was found to be significantly higher than that of the CCl ₄ × CMC group.

9, in rats with chronic hepatitis was induced by CCl _4, by using Sirius red staining, observation of fibrosis level of liver tissue, fibrosis level of CCl ₄ × oral tablet 1 times the dose of sets of liver tissue , CCl ₄ × CMC.

  According to the above experimental results, the oral tablet of the present invention has the following effects on liver damaged by carbon tetrachloride.

  1. It has the effect of reducing ALT and AST levels in plasma.

  2. It has the effect of increasing plasma albumin concentration.

  3. It has an inhibitory effect on spleen enlargement.

  4. It has the effect of increasing the soluble protein content of the liver.

  5. Has the effect of reducing liver fibrosis level.

  6. It has the effect of increasing the content of liver antioxidant (glutathione) and the activity of antioxidant enzyme (GSH-Px).

  The oral tablet of the present invention can be used to reduce the plasma ALT and AST levels in rats whose liver has been damaged by carbon tetrachloride, and to increase the activity of hepatic antioxidant enzymes (GSH-Px). 3. It has been found that by helping to reduce the level of liver fibrosis, it has a protective or improving effect on liver function.

10 Tablet body 20 Film coating layer

Claims (7)

An oral tablet,
A tablet body comprising a solid form formed by mixing the compound preparation in powder form, wherein the tablet body comprises a circular annular surface and two end surfaces connected to opposite ends of the annular surface; An oral tablet characterized in that each of the two end surfaces has a curved convex shape, and the composite preparation contains a turmeric extract, a rock extract, and other edible additives.   The oral tablet according to claim 1, further comprising a film coating layer covering an outer surface of the tablet body.   The oral tablet according to claim 2, wherein the turmeric extract is curcumin.   The oral tablet according to claim 3, wherein the curcumin accounts for 11.17% to 16.77% based on the weight percentage of the oral tablet.   The oral tablet according to any one of claims 1 to 4, wherein the Iwaenkei extract is salidroside.   6. The oral tablet according to claim 5, wherein said salidroside accounts for 0.12% to 0.18% based on the weight percentage of the oral tablet.   The oral tablet according to claim 6, wherein the other edible additives include taurine and corn gluten meal.

Images